WASHINGTON - US biotech firm Novavax's COVID-19 vaccine was shown to be 100 percent protective against severe cases of the disease, including hospitalization and death, the company said last Thursday following trials.
In a Phase 3 trial in Britain that included 15,000 participants aged 18-84, including 27 percent over the age of 65, efficacy against mild, moderate and severe COVID was 96.4 percent against the original strain. Across both trials, the vaccine known as NVX-CoV2373 demonstrated 100 percent protection against severe disease.
May mas tiwala pa ko rito kesa sa sinovac
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: